Chinese hamster ovary (CHO) cells represent the most frequently applied host cell system
for industrial manufacturing of recombinant protein therapeutics. CHO cells are capable of …

Aims This review is intended to update our previous discussion on the chemoenzymatic
synthesis of carbohydrates and glycoconjugates,(1) with new emphasis placed on …

The N-linked glycan profiles on recombinant monoclonal antibody therapeutics significantly
affect antibody biological functions and are largely determined by host cell genotypes and …

Chinese hamster ovarian cells (CHO) cells have been extensively utilized for industrial
production of biopharmaceutical products, such as monoclonal antibodies, human growth …

Over the past 20 years, we have seen significant improvements in product titres from 50 mg/l
to 5–10 g/l, a more than 100‐fold increase. The main methods that have been employed to …

Glycoengineering is increasingly being recognized as a powerful tool to generate
recombinant glycoproteins with a customized N-glycosylation pattern. Here, we demonstrate …

For several decades, glycoprotein biologics have been successfully produced from Chinese
hamster ovary (CHO) cells. The therapeutic efficacy and potency of glycoprotein biologics …

Sialic acid, a terminal residue on complex N‐glycans, and branching or antennarity can play
key roles in both the biological activity and circulatory lifetime of recombinant glycoproteins …

Therapeutic glycoproteins with exposed galactose (Gal) residues are cleared rapidly from
the bloodstream by asialoglycoprotein receptors in hepatocytes. Various approaches have …

Large‐scale transient expression in mammalian cells is a rapid protein production
technology often used to shorten overall timelines for biotherapeutics drug discovery. In this …